Absci (ABSI) Acquisitions (2021 - 2022)
Absci (ABSI) reported Acquisitions of $8.0 million for Q2 2022, down 68.77% on a YoY basis from $25.6 million in Q2 2021, and down 68.77% sequentially from $25.6 million in Q2 2021.
Absci (ABSI) Acquisitions (2021 - 2022) Analysis & Trends
Absci (ABSI) has 2 years of Acquisitions data on file, last reported at $8.0 million in Q2 2022.
- For the quarter ending Q2 2022, Acquisitions fell 68.77% year-over-year to $8.0 million; the trailing twelve-month figure through Sep 2023 stood at $8.0 million (changed 0.0% YoY), and the FY2022 full-year result was $8.0 million, down 71.56% from the prior year.
- Acquisitions retreated to $8.0 million in Q2 2022, from $25.6 million in the prior quarter.
- In the past five years, Acquisitions ranged from a high of $25.6 million in Q2 2021 to a low of $2.5 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Absci | 1.23 Bn | 1.11 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 8.00 Mn |
| Jun 30, 2021 | 25.62 Mn |
| Mar 31, 2021 | 2.51 Mn |